Science

Targeting the Next Generation of Immunotherapeutics

Natural peptides and proteins, together with their engineered analogs, have been a primary source of leads for the development of drugs, particularly in the oncology and infectious disease spaces. Engineered analogs utilize the building blocks of our natural chemistry by incorporating modifications that lead to enhanced efficacy and potency in drug candidates. Orion’s proprietary Drug Discovery Platform facilitates the rapid, systematic generation of new peptide and protein analogs that will enable a tailored approach for the treatment of diseases and allow patients to unlock the full potential of their immune system.

An Innovative Drug Discovery Platform

Optimized Phage Display

Ability to create millions of variants of targeted chemokine analogs and rapidly reproduce hundreds of optimized candidate hits

Proprietary Multiplex Chemical Synthesis

Efficiently and effectively implement new drug development by identifying leads with superior pharmacological activity

Robust and Scalable Toolset

Multiple drug candidates may be developed in parallel, enabling a highly scalable and robust system for discovery and development 

Chemokines

Chemokines are small signaling proteins that orchestrate the movement of immune cells throughout the body in order to maintain a healthy immune system, and as part of the response to infection and injury. Movement is controlled by activation of different chemokine receptors, which are expressed on a broad range of immune cells, and their chemokine ligands, which are produced in tissues. Chemokine expression is dysregulated in autoimmune disease, and there is growing evidence indicating that cancer, and other serious diseases, hijack the chemokine system to promote growth and spread through the body. Tumors release chemokines that attract immunosuppressive cells into the tumor microenvironment where they slow down attack by the immune system. Tumor cells can also acquire chemokine receptor expression, which facilitates metastasis. Consequently, drugs that block the interactions between chemokines and their receptors have the potential to modulate the immune system in order to treat a broad range of serious diseases including cancer and autoimmune disorders. Our lead chemokine analog targets, CCR5 and CCR9, were designed to overcome the barriers and disadvantages of current therapeutics by creating safe and extremely potent drug candidates, with broad applicability.

CCR5 Chemokine Analog

The chemokine receptor CCR5 has long been of interest in drug development for HIV prevention and therapy, but recently it has emerged as a target to treat several other diseases including cancer. CCR5 antagonism through OB-002 has shown encouraging performance in pre-clinical models of these diseases.

Tumors can both acquire CCR5 expression and secrete CCL5, one of its natural ligands. This gives the tumor a number of advantages including sustained proliferation of CCR5-positive tumor cells, recruitment of suppressive immune cells, promotion of neo-angiogenesis, and facilitation of metastasis.  Using OB-002 to block CCR5 has the potential to provide cancer patients with superior efficacy and an enhanced safety profile compared to those of current immuno-oncology therapies, as well as activity across multiple tumour types.

CCR9 Chemokine Analog

The chemokine receptor CCR9 is found primarily on a population of activated T cells which migrate selectively to the digestive tract. Intestinal inflammation can lead to a vicious circle of infiltration of activated T cells followed by release of proinflammatory signals from the tissue including CCL25, the natural ligand of CCR9, which in turn drives further infiltration of activated T cells. This inflammatory feedback loop drives Crohn’s disease and ulcerative colitis, two conditions collectively known as inflammatory bowel disease (IBD). Blocking the CCL25/CCR9 axis represents a promising strategy to combat IBD. CCR9/CCL25 has also been implicated in tumor metastasis and pathways involved in tumour chemoresistance and as such represents a promising new target for cancer therapy.

Global Headquarters

343 Preston Street

11th floor,

Ottawa, On K1S 1N4

CANADA

+1 343.291.1032

Switzerland

Campus Biotech

Innovation Park

Avenue de Sécheron 15

1202 Genève

SWITZERLAND

Poland

Orion Biotechnology

Life Science Park

UI Bobrzyńskiego 14

30-348 Krakôw

POLAND

© 2020 Orion Biotechnology Canada, Ltd.       |      Privacy Policy

Privacy Policy

©2020 Orion Biotechnology Canada, Ltd.       

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032